Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development

Rhea-AI Summary

Actuate Therapeutics (NASDAQ: ACTU) announced its participation in Lantern Pharma's 'Webinar Wednesday' on October 30, 2024. The webinar will feature Andrew Mazar, Ph.D., Actuate's Chief Operating Officer, and Joseph McDermott, Ph.D, Lantern's computational biologist, discussing their multi-year collaboration focused on accelerating the development of elraglusib, Actuate's lead drug candidate.

The collaboration aims to identify and develop enrichment biomarkers for elraglusib, a GSK-3β inhibitor currently in Phase 2 trials for metastatic pancreatic cancer and Phase 1/2 trials for Ewing Sarcoma and related sarcomas.

Positive

• Ongoing Phase 2 clinical trials for elraglusib in metastatic pancreatic cancer
• Additional Phase 1/2 trials in progress for Ewing Sarcoma
• Strategic collaboration with Lantern Pharma for biomarker development

Negative

• None.

• Companies will discuss how Lantern’s AI platform is being leveraged for the identification and development of enrichment biomarkers for Actuate’s lead investigational drug product, elraglusib

CHICAGO and FORT WORTH, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), announced that it will participate in “Webinar Wednesday” hosted by Lantern Pharma on October 30, 2024.

Andrew Mazar, Ph.D., Chief Operating Officer of Actuate Therapeutics, and Joseph McDermott, Ph.D, Lantern’s computational biologist will discuss the multi-year research and development collaboration that is accelerating the development of Actuate’s lead drug candidate, elraglusib, and enabling the screening for additional biomarkers to assess and predict its therapeutic activity and clinical outcomes.

To register for the webinar, please use the following link: https://bit.ly/3YsL2XN

Elraglusib is a novel GSK-3β inhibitor currently being evaluated in Phase 2 Trial in metastatic pancreatic cancer (NCT03678883) and Phase 1/2 Trial (NCT04239092) in Ewing Sarcoma (EWS) and EWS-related sarcomas.

About Actuate Therapeutics, Inc.

Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate’s lead investigational drug product, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy including EMT, NF-kB-mediated resistance and several DDR pathways. Elraglusib also acts as a mediator of anti-tumor immunity through the inhibition of NF-kB in immune cells and regulates multiple immune checkpoints and immune cell function. For additional information, please visit the Company’s website at http://www.actuatetherapeutics.com.

Forward-Looking Statements

This press release contains and the webinar referenced above will contain forward-looking statements about us, including our clinical trials and development plans, and our industry. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All statements, other than statements related to present facts or current conditions or of historical facts, contained in this press release and the webinar are forward-looking statements. Accordingly, these statements involve estimates, assumptions, substantial risks and uncertainties which could cause actual results to differ materially from those expressed in them, including but not limited to that clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes, results of prior preclinical studies and early clinical trials are not necessarily predictive of future results, and elraglusib may not achieve favorable results in clinical trials or preclinical studies or receive regulatory approval on a timely basis, if at all; that we may not successfully enroll additional patients or establish or advance plans for further development; that elraglusib could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude regulatory approval, cause us to suspend or discontinue clinical trials or result in other negative consequences; our reliance on third parties to conduct our non-clinical studies and our clinical trials; our reliance on third-party licensors and ability to preserve and protect our intellectual property rights; that we face significant competition from other biotechnology and pharmaceutical companies; and our ability to fund development activities. In addition, any forward-looking statements are qualified in their entirety by reference to the factors discussed under the heading “Risk Factors” in our Form 10-Q filed with the SEC on September 24, 2024 and other filings with the SEC. Because the risk factors referred to above could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Unless legally required, we do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date of this press release or the webinar or to reflect the occurrence of unanticipated events.

Investor Contact

Mike Moyer

Managing Director

LifeSci Advisors, LLC

mmoyer@lifesciadvisors.com

FAQ

What is the purpose of Actuate Therapeutics (ACTU) and Lantern Pharma's webinar on October 30, 2024?

The webinar will discuss their collaboration on using AI for identifying and developing enrichment biomarkers for Actuate's lead drug candidate, elraglusib.

What clinical trials is Actuate Therapeutics (ACTU) currently conducting for elraglusib?

Actuate is conducting a Phase 2 trial for metastatic pancreatic cancer (NCT03678883) and a Phase 1/2 trial (NCT04239092) for Ewing Sarcoma and EWS-related sarcomas.

What is the primary target of Actuate Therapeutics' (ACTU) drug elraglusib?

Elraglusib is a novel GSK-3β (glycogen synthase kinase-3 beta) inhibitor designed for treating high-impact, difficult-to-treat cancers.